Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer

Timothy N. Clinton, Solomon L. Woldu, Ganesh V. Raj

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy. Expert opinion: Degarelix represents a newer class of ADT that results in a rapid and reliable decline in serum testosterone, a quality that makes it particularly advantageous in men presenting with symptomatic, hormone-sensitive prostate cancer. Due to differences in mechanism of action, there is observational data suggesting a potential cardiovascular and even oncologic benefit over traditional LHRH agonist therapy. Further research is ongoing to more clearly define this potential benefit.

Original languageEnglish (US)
Pages (from-to)825-832
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number8
DOIs
StatePublished - May 24 2017

Fingerprint

Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Androgens
Hormone Antagonists
Therapeutics
Hormones
Castration
Expert Testimony
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
Testosterone
Pharmacokinetics
Serum
Research

Keywords

  • androgen deprivation therapy
  • Degarelix
  • GnRH antagonist
  • LHRH agonist
  • prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. / Clinton, Timothy N.; Woldu, Solomon L.; Raj, Ganesh V.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 8, 24.05.2017, p. 825-832.

Research output: Contribution to journalReview article

@article{24f5b7eb0a0c44eba1f37051be3305e4,
title = "Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer",
abstract = "Introduction: Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy. Expert opinion: Degarelix represents a newer class of ADT that results in a rapid and reliable decline in serum testosterone, a quality that makes it particularly advantageous in men presenting with symptomatic, hormone-sensitive prostate cancer. Due to differences in mechanism of action, there is observational data suggesting a potential cardiovascular and even oncologic benefit over traditional LHRH agonist therapy. Further research is ongoing to more clearly define this potential benefit.",
keywords = "androgen deprivation therapy, Degarelix, GnRH antagonist, LHRH agonist, prostate cancer",
author = "Clinton, {Timothy N.} and Woldu, {Solomon L.} and Raj, {Ganesh V.}",
year = "2017",
month = "5",
day = "24",
doi = "10.1080/14656566.2017.1328056",
language = "English (US)",
volume = "18",
pages = "825--832",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer

AU - Clinton, Timothy N.

AU - Woldu, Solomon L.

AU - Raj, Ganesh V.

PY - 2017/5/24

Y1 - 2017/5/24

N2 - Introduction: Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy. Expert opinion: Degarelix represents a newer class of ADT that results in a rapid and reliable decline in serum testosterone, a quality that makes it particularly advantageous in men presenting with symptomatic, hormone-sensitive prostate cancer. Due to differences in mechanism of action, there is observational data suggesting a potential cardiovascular and even oncologic benefit over traditional LHRH agonist therapy. Further research is ongoing to more clearly define this potential benefit.

AB - Introduction: Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy. Expert opinion: Degarelix represents a newer class of ADT that results in a rapid and reliable decline in serum testosterone, a quality that makes it particularly advantageous in men presenting with symptomatic, hormone-sensitive prostate cancer. Due to differences in mechanism of action, there is observational data suggesting a potential cardiovascular and even oncologic benefit over traditional LHRH agonist therapy. Further research is ongoing to more clearly define this potential benefit.

KW - androgen deprivation therapy

KW - Degarelix

KW - GnRH antagonist

KW - LHRH agonist

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85019899843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019899843&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1328056

DO - 10.1080/14656566.2017.1328056

M3 - Review article

C2 - 28480768

AN - SCOPUS:85019899843

VL - 18

SP - 825

EP - 832

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -